Yes indeed, Eupraxia Pharmaceutical’s (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time.
A Chronic Disease Finally Meets a Long-Term Plan
Eosinophilic esophagitis (EoE) has matured from “zebra” to mainstream GI diagnosis, with roughly 500,000 known U.S. cases and credible arguments that the real number is closer to one million. Emergency room data showing hundreds of thousands of young men with classic symptoms but no code in the chart suggest the epidemiology is still catching up to reality. As awareness grows, experts expect the pool of diagnosed patients to double or even triple over the next 5–10 years, turning EoE from niche to necessary line item on every GI group’s strategic plan. For now, diagnosis still requires endoscopy with biopsy—there is no non-endoscopic shortcut—cementing the procedure suite as both the diagnostic and, increasingly, therapeutic center of gravity.
Today’s EoE Playbook: Effective, Fragmented, and Tiring
Modern EoE care offers an impressive menu, with three first-line strategies all considered reasonable at the opening whistle: diet, proton pump inhibitors (PPIs), and topical steroids. Elimination diets work but demand commitment: dairy alone converts about 35–40% of patients, dairy plus wheat nudges response toward 40–45%, and full six-food regimens can push efficacy to roughly 60%, at the cost of a social life built around ingredient lists. PPIs deliver a 30–40% histologic response in EoE—not because they neutralize acid, but because they act as anti-inflammatory agents upstream in the cascade. Swallowed topical steroids, often adapted from asthma formulations, reliably produce 50–60% histologic responses but require meticulous daily technique most teenagers abandon after about three good weeks.
Regulatory-grade options are finally here as well: Takeda’s (NYSE: TAK) Eohilia, an FDA‑approved budesonide oral suspension, delivered around a 53% histologic response over 12 weeks with measurable improvements in Dysphagia Symptom Questionnaire scores. In Europe, Canada, and Australia, the budesonide tablet Jorveza posts 80–90% symptom response and 50–60% histologic response, illustrating what a purpose-built esophageal steroid can do when it doesn’t rush through the esophagus in a few seconds.
The Biologic Era: Potent but Positioned Second
For patients who fail PPIs and often steroids, Sanofi’s (NASDAQ: SNY) massively marketed dupilumab (Dupixent) (~18.7B in sales in 2025) has reshaped the second-line conversation, with roughly 55–60% histologic response and sustained improvements in endoscopic and histologic scores through 52 weeks. In pivotal studies, all patients had already failed PPIs and most had failed steroids, underscoring that the drug is operating in a difficult, treatment-experienced population. Current practice and payer behavior largely reserve dupilumab for those who have exhausted simpler options, with earlier use mainly considered when multiple severe allergic comorbidities already justify biologic therapy. The irony, of course, is that the patients most allergic to everything often end up allergic to the stepwise logic of prior authorization as well.
Why EP-104 Looks Different
EP-104GI, Eupraxia’s long-acting fluticasone injectable, is explicitly designed to invert the rhythm of EoE care: one procedural moment, months of pharmacology. The drug consists of polymer‑coated fluticasone crystals injected into the esophageal wall, where they release steroid at a controlled rate with a low peak concentration and extended tail. The goal is straightforward but ambitious: at least six months of symptom control and histologic improvement from a single session, with emerging one‑year data suggesting that “annual maintenance endoscopy plus injection” is a realistic scenario in higher-dose cohorts. Early RESOLVE trial results show durable improvements in the EoE Histologic Scoring System (EoEHSS), with roughly 47% improvement in grade and 44% in stage at week 36 for patients receiving 4 mg per injection, alongside sustained clinical remission rates on the Straumann Dysphagia Index out to week 52.
Strategically, EP-104 is not going after the biologic‑heavy third‑line corner but the broad center of the market: newly or recently diagnosed patients for whom topical steroids are being considered, regardless of whether their disease is mild, moderate, or severe. Excluding the roughly one‑third of patients who respond adequately to PPIs, KOL estimates suggest 60–70% of the diagnosed EoE population could plausibly fit a long‑acting injectable steroid strategy—if the data hold in placebo‑controlled trials and payers accept the procedural economics.
The Histology Story: Beyond Just Killing Eosinophils
EP-104’s development program leans heavily on the EoE Histologic Scoring System, which grades and stages eight separate features including non‑eosinophilic inflammation, barrier disruption, fibrosis, and epithelial architecture. This is deliberate, because EoE’s natural history is stubborn: the disease does not spontaneously remit, and placebo effects on biopsy-based measures are typically minimal. Experience with eosinophil‑depleting biologics such as benralizumab and mepolizumab shows that driving eosinophils toward zero can yield impressive histologic counts without corresponding improvements in endoscopic appearance or symptoms, underscoring that eosinophils are the final effector step, not the command center. Broad anti‑inflammatory steroids that bathe the full inflammatory cascade, on the other hand, consistently correlate with better tissue remodeling and symptom trajectories even when eosinophil reduction is less dramatic. This is precisely the lane EP-104 is trying to occupy—only with the pharmacokinetics shifted from “twice a day” to “see you next endoscopy.”
Symptoms, Scores, and the Placebo Problem
If biopsies are refreshingly stoic, patient‑reported outcomes are anything but. Placebo response rates of roughly 40% for a 30% improvement threshold on dysphagia scales are common, as patients adjust eating behavior, expectations, and anxiety as much as their mucosa. EP-104’s early program used the Straumann Dysphagia Index but, aligning with FDA guidance and industry precedent from Eohilia and dupilumab, is pivoting to the Dysphagia Symptom Questionnaire (DSQ) for pivotal work. In prior large trials, active therapies have typically doubled the absolute DSQ improvement seen with placebo, with 7–14 point changes on the 0–84 scale for placebo arms and substantially larger shifts in treated groups. To preserve blinding in a procedural therapy, the phase 2B EP-104 study uses sham injections, ensuring that every patient undergoes endoscopy and injection maneuvers regardless of study arm—a design choice that may prevent the “I felt the needle, so I must be on drug” bias that would otherwise haunt the data.
Fibrosis, Dilation, and Remodeling the Esophagus
Roughly 15–20% of EoE patients live in the severe category, with daily symptoms, food impactions, emergency visits, and strictures that can resemble a straw more than an esophagus. Another 40% sit in the mild bucket and about 40% in the moderate range, but even in these groups, silent fibrosis can accumulate over years. The reassuring news is that fibrosis is not destiny: multiple treatment classes, including topical steroids and biologics, have demonstrated the ability to reverse fibrosis in both pediatric and adult cohorts, with EndoFLIP measurements documenting several‑millimeter increases in esophageal caliber after successful anti‑inflammatory therapy. Achieving histologic remission sharply reduces future dilation requirements and, when dilations are performed against a background of controlled inflammation, the resulting caliber gains tend to plateau rather than rapidly re‑narrow. For EP-104, which sits directly in the esophageal wall for months, the prospect of sustained anti‑fibrotic impact is central to the commercial narrative and will likely be scrutinized as closely as symptom scores in longer-term data cuts.
Logistics, Endoscopy Suites, and the Business of Better Care
From an implementation standpoint, EP-104 asks GI physicians to do something they already do, just in a new indication. Endoscopists routinely inject Botox for achalasia, epinephrine for bleeding, and triamcinolone for refractory strictures; adding a few esophageal wall injections during a standard 10–15 minute upper endoscopy is more evolution than revolution. The EP-104 procedure adds roughly 10 minutes and introduces a more complex, higher‑value billing profile, which in most U.S. practice models is an argument in favor of adoption rather than a barrier. The comparison that may quietly sell the concept in the physician’s lounge is triamcinolone: aqueous steroid injections currently wash out within days, missing the crucial seven-plus‑day window required for meaningful tissue remodeling, whereas EP-104 is purpose‑built to sit tight and work slowly. For practices that already see EoE patients annually for surveillance endoscopy, the idea of folding definitive steroid therapy into that same visit has a certain operational elegance.
Management models will differ: in some regions allergists “own” the patient and GI acts as procedural consultant, while in others gastroenterologists lead and allergists handle comorbid atopic disease. A long‑acting endoscopic therapy naturally pulls some gravity toward the endoscopy suite, but the highest‑functioning systems will likely land on genuine co‑management rather than turf wars, particularly given the high rate of overlapping asthma, atopic dermatitis, and food allergy in this population.
Market Scope Today and Tomorrow
If EP-104 ultimately secures a first‑line steroid label, its natural habitat would be the 60–70% of diagnosed EoE patients who either fail or prefer not to rely on PPIs and are candidates for topical steroids. With current U.S. prevalence around 500,000 diagnosed cases and a probable real prevalence near one million, a doubling or tripling of diagnosed patients over the coming decade would place the addressable pool comfortably into the high six to low seven figures. Against that backdrop, an annual or semi‑annual endoscopic injection strategy does not need every patient to sign up to be a meaningful business; it merely needs to become the standard play for a clearly defined segment that values convenience, durability, and procedural certainty.
Beyond EoE, the company and external experts have begun to sketch out a broader canvas that includes other inflammatory and fibrotic esophageal conditions and stricturing diseases elsewhere in the GI tract. There is currently no long‑acting steroid injection designed for the gastrointestinal tract, and clinicians already frequently inquire about adapting EP-104‑like approaches for refractory strictures, suggesting “many tens of thousands” of potential additional patients across indications if the platform proves modular. It is early, but the outlines of a procedural, steroid‑delivery franchise—not just a single EoE product—are visible.
The Next Readout: Data, Duration, and Definition of Success
The next major inflection point comes with placebo‑controlled phase 2B data, expected later this year, which will need to confirm not just histologic and endoscopic benefits but also a robust effect on DSQ scores in the face of a substantial placebo response. Simultaneously, ongoing follow‑up in higher‑dose cohorts should refine the real‑world redosing interval—whether six, nine, or twelve months becomes the standard, and whether annual “scope and inject” truly holds up as a durable regimen. If those pieces fall into place, EP-104 could reframe EoE care from a daily reminder of chronic disease to a scheduled procedure that most patients think about roughly as often as their car’s oil change.
For patients, the value proposition is disarmingly simple: swap a daily ritual of swallowing medicine that may or may not fit their life for a once‑or‑twice‑a‑year procedure that aligns with the way the disease is already monitored. For investors, the more interesting question is whether EP-104 becomes the default first‑line steroid in a rapidly expanding EoE market—or merely a high‑end option for a motivated subset of patients and physicians comfortable with procedural solutions.
The Sources
- EP-104GI RESOLVE Clinical Trial Overview (NCT05608681) – ClinicalTrials.gov
https://clinicaltrials.gov/study/NCT05608681clinicaltrials - EP-104GI Long-Acting Fluticasone Injectable in EoE – Eupraxia ISDE 2024 Poster (PDF)
https://www.eupraxiapharmaceuticals.com/wp-content/uploads/2025/08/2024_09_10_ISDE-2024-EoE-poster_FINAL.pdfeupraxiapharmaceuticals - EP-104GI Performs Well in Eosinophilic Esophagitis Trial – PatientWorth y Article
https://patientworthy.com/2024/06/11/ep104gi-performs-well-eosinophilic-esophagitis-eoe-trial/patientworthy - Eupraxia Announces Positive Data from RESOLVE Phase 1b/2a Trial – Press Release
https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-announces-positive-data-from-resolve-phase-1b2a-trial-of-ep-104gi-for-treatment-of-eosinophilic-esophagitis-301414725.htmlprnewswire - Eupraxia Reports Near-Complete Biopsy Improvement in RESOLVE Trial – CheckOrphan
https://checkorphan.org/news/eupraxia-reports-near-complete-biopsy-improvement-in-resolve-eosinophilic-esophagitis-trial/checkorphan - Eupraxia Reports Six-Month Symptom Data from Highest-Dose Cohort – Yahoo Finance
https://finance.yahoo.com/news/eupraxia-pharmaceuticals-reports-six-month-110000698.htmlfinance.yahoo - Eupraxia EoE Trial Update – Clinical Trials Arena
https://www.clinicaltrialsarena.com/news/eupraxia-eosinophilic-esophagitis-trial/clinicaltrialsarena - FDA Approves EOHILIA (Budesonide Oral Suspension) for EoE – Takeda News
https://www.takeda.com/newsroom/newsreleases/2024/fda-approves-eohilia/takeda - EOHILIA (Budesonide Oral Suspension) Prescribing and Clinical Use Summary – Formulary Document
https://fm.formularynavigator.com/FormularyNavigator/DocumentManager/Download?clientDocumentId=SEuoQkEHrUeMnZTlARTGDQformularynavigator - EOHILIA (Budesonide) FDA Review Documentation (Other Review) – FDA
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/213976Orig1s000OtherR.pdfaccessdata.fda - EOHILIA (Budesonide) FDA Label – FDA
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213976s000lbl.pdfaccessdata.fda - Efficacy and Safety of Dupilumab up to 52 Weeks in Adults and Adolescents with EoE – PubMed / Lancet
https://pubmed.ncbi.nlm.nih.gov/37660704/pubmed.ncbi.nlm.nih - Dupilumab Improves Inflammatory and Remodeling Aspects of EoE: 52-Week LIBERTY EoE TREET Data (PDF) – Sanofi Medical Congress
https://congress.sanofimedical.com/s3fs-public/2024-05/Dupilumab%20Improves%20Inflammatory%20and%20Remodeling%20Aspects%20of%20Eosinophilic%20Esophagitis%20-%2052-Week%20Results%20From%20the%20Phase%203%20LIBERTY%20EoE%20TREET%20Study.pdfcongress.sanofimedical - Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from RESOLVE Trial – Company Press Release
https://www.biospace.com/press-releases/eupraxia-pharmaceuticals-reports-six-month-symptom-data-from-the-highest-dose-cohort-in-the-resolve-trial-in-eosinophilic-esophagitis.htmlbiospace
